These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 22950382

  • 1. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
    Aurpibul L, Chotirosniramit N, Sugandhavesa P, Kosashunhanan N, Thetket S, Supindham T, Piyamongkol W, Supparatpinyo K.
    Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
    [Abstract] [Full Text] [Related]

  • 2. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
    Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V.
    Antivir Ther; 2009 Dec; 14(3):315-20. PubMed ID: 19474465
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    Ngayo MO, Oluka M, Kwena ZA, Bulimo WD, Okalebo FA.
    PLoS One; 2022 Feb; 17(3):e0260872. PubMed ID: 35235559
    [Abstract] [Full Text] [Related]

  • 7. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W.
    Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
    [Abstract] [Full Text] [Related]

  • 8. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
    Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S.
    Biochem Biophys Res Commun; 2004 Jul 09; 319(4):1322-6. PubMed ID: 15194512
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E.
    Clin Pharmacol Ther; 2011 Sep 09; 90(3):406-13. PubMed ID: 21814190
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, Shen L, Ma Q, Lu H, Cai W.
    PLoS One; 2015 Sep 09; 10(6):e0130583. PubMed ID: 26107645
    [Abstract] [Full Text] [Related]

  • 14. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
    Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH.
    AIDS; 2009 Oct 23; 23(16):2101-6. PubMed ID: 19779319
    [Abstract] [Full Text] [Related]

  • 15. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
    Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y.
    Eur J Clin Pharmacol; 2012 Mar 23; 68(3):267-71. PubMed ID: 21901344
    [Abstract] [Full Text] [Related]

  • 16. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico.
    Ortíz-Rodríguez MA, Oaxaca-Navarro J, Patiño-Camacho SI, García-Jiménez S, Déciga-Campos M, Martínez-Salazar MF.
    Pharmazie; 2022 Jun 01; 77(6):191-195. PubMed ID: 35751161
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.
    To KW, Liu ST, Cheung SW, Chan DP, Chan RC, Lee SS.
    Ther Drug Monit; 2009 Aug 01; 31(4):527-30. PubMed ID: 19531981
    [Abstract] [Full Text] [Related]

  • 18. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
    Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Décosterd L, Telenti A, Swiss HIV Cohort Study.
    Pharmacogenet Genomics; 2005 Jan 01; 15(1):1-5. PubMed ID: 15864119
    [Abstract] [Full Text] [Related]

  • 19. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P, Avihingsanon A, Manosuthi W, Ubolyam S, Tongkobpetch S, Shotelersuk V, Punyawudho B.
    Clin Ther; 2020 Jul 01; 42(7):1234-1245. PubMed ID: 32451120
    [Abstract] [Full Text] [Related]

  • 20. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH.
    Ther Drug Monit; 2012 Apr 01; 34(2):153-9. PubMed ID: 22354160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.